Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
Funding for innovative projects on new treatment modalities such as targeted therapies and immune therapies.
Característiques principals
The 2021 LCRF-AstraZeneca grant program aims to fund innovative projects to:
  • Understand primary and acquired resistance to osimertinib and novel combinations targeting concurrent driver mutations
  • Develop more effective approaches to address disease progression in patients treated with durvalumab
  • Discover novel biomarkers for predicting response to osimertinib or durvalumab and to identify patients who are at higher risk of recurrence (translational research preferred)
  • Identify predictive biomarkers, understand the underlying biology and develop novel interventions for immune mediated adverse events, such as pneumonitis, in patients receiving durvalumab
    Proposals which specifically focus on either osimertinib or durvalumab will be strongly favored.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Marta López: mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    https://www.lungcancerresearchfoundation.org/research/funding-opportunities/
    Informació addicional
    Applications must be submitted through a two-stage process:
  • A letter of intent (LOI): deadline April 30th
  • A full proposal(under invitation); deadline August 27th
    • Requisits
    Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment.
    Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status. Senior investigators with more than ten years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than ten years’ experience in other disease areas or topics. Ineligible investigators with these or other special circumstances may request review by contacting the LCRF grants office (see Inquiries section below).
    Dotació
    $150,000 for a period of two years (disbursed at $75,000 per year)
    Durada
    2 years
    Documentació
    All applications must be submitted through LCRF's online grants management system:
    https://lcrf.org/grantinterface
    Previews of the LOI and full application may be accessed at http://lcrf.org/application_preview

    Arxius

    Arxiu
    RFP-2021-LCRF-AstraZeneca-Grant-Program-FINAL.pdf